Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Meropenem-vaborbactam (Vabomere) is the latest &beta;-lactam/&beta;-lactamase inhibitor (BLI), approved by the FDA in August 2017 for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, and <em>Enterobacter cloacae</em> species complex in adults older than 18 years of age.</p>

Meropenem-vaborbactam